BioNTech Stock Rises After Earnings. Pfizer's Vaccine Partners Is Battling a Covid Downturn.

  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 51 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 24%
  • Publisher: 97%

Malaysia News News

Malaysia Malaysia Latest News,Malaysia Malaysia Headlines

Shares have dropped 36% this year as demand for its coronavirus inoculations has fallen.

BioNTech, the German pharmaceutical company that partnered with Pfizer to create a Covid-19 vaccine, posted a surprise earnings beat.

For the third quarter, earnings per share came in at 0.67 euros , compared with analysts’ expectations for a loss in the period. Revenue also topped estimates, at €895 million , though both figures were lower than a year ago. The company also said that it wouldn’t have to take as big a hit on its Covid-19 vaccines as it thought just a few weeks ago. It said it would reduce third-quarter revenues by €508 million after Pfizer reported writedowns on their joint product. It initially said it could be about €900 million.

BioNTech U.S.-listed shares jumped more than 3% in premarket trading. BioNTech stock has declined 36% this year. Pfizer , which reported disappointing earnings last week, was up 0.2% in early trading Monday. Covid-19 vaccine makers have been shunned after their meteoric rise during the pandemic. BioNTech and peers such as Pfizer and Moderna are having trouble convincing investors they are more than one-trick ponies.Write to Brian Swint at brian.swint@barrons.com

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 3. in MY
 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

Malaysia Malaysia Latest News, Malaysia Malaysia Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Pfizer Covid Vaccine Partner BioNTech's Stock Is Rising After Earnings BeatShares have dropped 36% this year as demand for its coronavirus inoculations has fallen.
Source: MarketWatch - 🏆 3. / 97 Read more »